Abstract& Key message This article presents the leaching, fire and weathering resistance improvements of samples treated with tannin-based wood preservatives added of caprolactam. PEG-added formulations show limited applicability. The FT-IR and 13 C-NMR analyses of the caprolactam-added formulations show some evidences of copolymerization.

Aim: This real-world analysis evaluated docetaxel plus nintedanib in patients with advanced pulmonary adenocarcinoma after chemotherapy and immune checkpoint inhibitor failure, for whom treatment options are limited. Methods: Data were sourced retrospectively from seven German centers. Results: Of 93 patients, overall response rate was 41.4% (disease control rate: 75.9%). Of 57 patients given third-line docetaxel plus nintedanib, overall response rate was 50.0% (disease control rate: 82.7%). Median overall survival following third-line docetaxel plus nintedanib was 8.4 months. Adverse events were consistent with the known safety profile of docetaxel plus nintedanib. Conclusion: To date, this was the largest retrospective, real-world analysis of docetaxel plus nintedanib after chemotherapy–immunotherapy failure, indicating that docetaxel plus nintedanib offers meaningful clinical benefits in this setting.

SummaryThe purification of raw beeswax by melting produces a semi‐solid beeswax by‐product (BBR) composed by honey, resins and other constituents that is usually considered as a waste. In this article, the chemical characterisation of BBR is reported, with the aim to valorise this by‐product following the principles of the circular economy. Carbohydrates, hydrocarbons and minerals were among the main constituents. Flavonoids and phenolic acids represent 1.5% of the BBR, and their qualitative profile resembles the propolis. To assess its potential usefulness, the BBR was tested against gram‐positive and gram‐negative bacteria of clinical interest, and results were compared with the raw propolis. Klebsiella pneumoniae and Salmonella enterica were inhibited at concentrations ≥ 0.001 mg mL−1, while Enterococcus faecalis and methicillin‐resistant Staphylococcus aureus from 0.01 mg mL−1. Only BBR was active on Pseudomonas aeruginosa. Below the concentration of 1 mg mL−1, no significant toxicity on Caco2 cells was observed. These results indicate that the BBR presents a polyphenol composition similar to propolis and a significant antibacterial activity. Thus, on the basis of these results, we suggest that the BBR can represent a sustainable alternative to propolis as food preservative or nutraceutical.

No abstract

In cohort B, median age was 62 years (range: 41 e 80), 34/65 pts (52.3%) were men, and 47/65 pts (72.3%) were ECOG PS 0/1. 1st line treatments included pemetrexed (43/65 pts, 66.2%), cisplatin (31/65 pts, 47.7%), carboplatin (39/65 pts, 60.0%), bevacizumab (13/65 pts, 20.0%), vinorelbine (13/65 pts, 20.0%), paclitaxel (10/65 pts, 15.4%). 2nd line treatments included nivolumab, pembrolizumab, and atezolizumab. Under nintedanib and docetaxel, ORR was 50% (26/52 pts); DCR was 82.7% (43/52 pts). Median PFS was 6.5 months (95%CI 4.8 e 7.3), median OS was 12.2 months (95%CI 11.4 e 14.1). Treatment emergent adverse events (TEAEs) grade 3, serious TEAEs, and TEAEs leading to discontinuation were observed in 36/65 pts (55.4%), 34/65 pts (52.3%), and 22/65 pts (33.9%), respectively. Conclusions:The data show that nintedanib + docetaxel provides encouraging and clinically meaningful efficacy and a manageable safety profile in this patient population, providing further evidence for the use in lung adenocarcinoma following ICIs and chemotherapy.Clinical trial identification: NCT02392455.